Displaying drugs 12226 - 12250 of 12494 in total
ATG-101
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile.
Investigational
Matched Description: … ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive …
Luveltamab tazevibulin
Luveltamab tazevibulin, formerly known as STRO-002, is novel homogeneous folate receptor alpha (FolRα) targeting antibody-drug conjugate. It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer).
Investigational
Matched Description: … [A257414] It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate …
Litifilimab
Litifilimab is under investigation in clinical trial NCT05531565 (A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) And/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory And/or Intolerant to Antimalarial Therapy).
Investigational
Matched Description: … Litifilimab is under investigation in clinical trial NCT05531565 (A Study to Assess the Efficacy and Safety of …
D-threo-neopterin
A pteridine derivative present in body fluids; elevated levels result from immune system activation, malignant disease, allograft rejection, and viral infections. (From Stedman, 26th ed) Neopterin also serves as a precursor in the biosynthesis of biopterin.
Experimental
Matched Description: … (From Stedman, 26th ed) Neopterin also serves as a precursor in the biosynthesis of biopterin. …
Nanoparticle Epirubicin
Nanoparticle Epirubicin is under investigation in clinical trial NCT03168061 (Dose-escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma). It is a novel epirubicin drug-conjugated polymeric micelle.
Investigational
Matched Description: … Epirubicin is under investigation in clinical trial NCT03168061 (Dose-escalation and Expansion Trial of …
ZB131
ZB131 is a monoclonal antibody with a high affinity and specificity for cancer-specific plectin (CSP), a cell surface protein identified in a wide range of cancers that correlates with poor prognosis and aggressive tumors.
Investigational
Matched Description: … and specificity for cancer-specific plectin (CSP), a cell surface protein identified in a wide range of …
MVR-T3011
MVR-T3011 is a genetically modified oncolytic Herpes Simplex Virus (HSV-1) with 2 exogenous genes encoding the active heterodimer human interleukin 12 (IL-12) and the Fab fragment of an anti-human PD-1 antibody.
Investigational
Matched Description: … 2 exogenous genes encoding the active heterodimer human interleukin 12 (IL-12) and the Fab fragment of …
MK-8777
MK-8777 is under investigation in clinical trial NCT00610649 (Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)).
Investigational
Matched Description: … NCT00610649 (Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of …
AGS-004
AGS-004 is a personalized RNA-loaded dendritic cellbased
immunotherapy that is designed to stimulate the patient’s immune system to target and destroy the patient’s own unique viral burden. Non-personalized HIV immunotherapies are unable to raise cytotoxic T lymphocytes against HIV antigens, fail to induce T cell memory, and, most importantly, do...
Investigational
Matched Description: … a better chance of success for HIV treatment. ... This approach may overcome the weaknesses of other available therapies and therefore could result in …
ACR325
ACR325 is developed for the treatment of Parkinson’s disease and psychoses, including bipolar disorder, for which disease existing therapies have only limited effect and considerable adverse side effects. ACR325 is a dopaminergic stabiliser, which has demonstrated promising results in disease models for motor functions and psychoses.
Investigational
Matched Description: … ACR325 is developed for the treatment of Parkinson’s disease and psychoses, including bipolar disorder …
Subasumstat
Subasumstat is under investigation in clinical trial NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)).
Investigational
Matched Description: … NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of …
RO7300490
RO7300490 is an investigational Fibroblast Activation Protein-α (FAP) targeted CD40 agonist. RO7300490 is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors).
Investigational
Matched Description: … in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of …
Lixmabegagene relduparvovec
Lixmabegagene relduparvovec, formerly known as LYS-GM101, is a recombinant adeno-associated virus vector serotype rh.10 (AAVrh.10) carrying the human β-galactosidase gene (GBL1). It is under development for the treatment of GM1 gangliosidosis.
Experimental
Matched Description: … It is under development for the treatment of GM1 gangliosidosis.[L45929] …
GALE-301
GALE-301 is an investigational cancer immunotherapy. It is made up of E39, an immunogenic peptide derived from the folate binding protein (FBP), and an immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF).[A254696,L44166,L44171]
Investigational
Matched Description: … It is made up of E39, an immunogenic peptide derived from the folate binding protein (FBP), and an immune …
Nisevokitug
Nisevokitug is a monoclonal antibody targeted against transforming growth factor beta (TGFβ) under investigation in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients).
Investigational
Matched Description: … NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of …
Galidesivir
Galidesivir is an adenosine analogue that has been investigated for use against Zaire Ebolavirus. In animal studies, galidesivir was effective in increasing the survival rates from infections caused by various pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses. In vitro, it displayed broad-spectrum antiviral activity against various negative- and...
Investigational
Matched Description: … [L12039,L12084] Phase 1 clinical trials have begun to determine the safety of this drug in humans. ... [L12042] Because of its activity against other coronaviruses, it may be studied as a potential therapy …
Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)
The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system[F4738, A226853]. In pre-clinical trial testing on mice, rabbits, and non-human primates, the candidate was able to induce a functional antibody response within 7-14 days of initial injection . It...
Investigational
Matched Description: … non-human primates, the candidate was able to induce a functional antibody response within 7-14 days of ... The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding …
OBE101
OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine. Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management...
Investigational
Matched Description: … repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of …
TD-2749
TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome (C-IBS), opioid-induced constipation, functional dyspepsia and diabetic gastroparesis.
Investigational
Matched Description: … TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug …
Giloralimab
Giloralimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination With IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis).
Investigational
Matched Description: … NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of …
CMLVAX100
CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia. It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.
Investigational
Matched Description: … It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial. …
Zotiraciclib
Zotiraciclib is under investigation in clinical trial NCT02942264 (Zotiraciclib (TG02) Plus Dose-dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma).
Investigational
Matched Description: … Zotiraciclib (TG02) Plus Dose-dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of …
Pyruvaldehyde
An organic compound used often as a reagent in organic synthesis, as a flavoring agent, and in tanning. It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated cell preparations, in various culture media, and in vivo in certain animals. [PubChem]
Experimental
Matched Description: … It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated …
Sonepcizumab
A humanized monoclonal antibody directed against sphingosine 1-phosphate (S1P) with potential antiangiogenic and antineoplastic activities. Upon administration, sonepcizumab binds S1P, which may result in the inhibition of tumor angiogenesis. S1P is the extracellular ligand for the G protein-coupled lysophospholipid receptor EDG-1 (endothelial differentiation gene-1).
Investigational
Matched Description: … Upon administration, sonepcizumab binds S1P, which may result in the inhibition of tumor angiogenesis …
NGN-401
NGN-401 is a recombinant serotype 9 adeno-associated virus (AAV) encoding an intron encoding a miRNA generating sequence, complementary miRNA binding sites and a full-length human methyl cytosine binding protein 2 (MECP2). Developed by Neurogene Inc., it is being investigated for the treatment of Rett syndrome.
Investigational
Matched Description: … ., it is being investigated for the treatment of Rett syndrome. …
Displaying drugs 12226 - 12250 of 12494 in total